218 related articles for article (PubMed ID: 31010589)
21. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
22. Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway.
Volckmar AL; Leichsenring J; Flechtenmacher C; Pfarr N; Siebolts U; Kirchner M; Budczies J; Bockmayr M; Ridinger K; Lorenz K; Herpel E; Noske A; Weichert W; Klauschen F; Schirmacher P; Penzel R; Endris V; Stenzinger A
Genes Chromosomes Cancer; 2017 Jan; 56(1):11-17. PubMed ID: 27438523
[TBL] [Abstract][Full Text] [Related]
23. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Troxell ML; Levine J; Beadling C; Warrick A; Dunlap J; Presnell A; Patterson J; Shukla A; Olson NR; Heinrich MC; Corless CL
Mod Pathol; 2010 Jan; 23(1):27-37. PubMed ID: 19898424
[TBL] [Abstract][Full Text] [Related]
24. Sclerosing Polycystic Adenoma of Salivary Glands: A Novel Neoplasm Characterized by PI3K-AKT Pathway Alterations-New Insights Into a Challenging Entity.
Skálová A; Baněčková M; Laco J; Di Palma S; Agaimy A; Ptáková N; Costes-Martineau V; Petersson BF; van den Hout MFCM; de Rezende G; Klubíčková N; Koblížek M; Koshyk O; Vaneček T; Leivo I
Am J Surg Pathol; 2022 Feb; 46(2):268-280. PubMed ID: 34510113
[TBL] [Abstract][Full Text] [Related]
25. Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
Zięba S; Kowalik A; Zalewski K; Rusetska N; Goryca K; Piaścik A; Misiek M; Bakuła-Zalewska E; Kopczyński J; Kowalski K; Radziszewski J; Bidziński M; Góźdź S; Kowalewska M
Gynecol Oncol; 2018 Sep; 150(3):552-561. PubMed ID: 29980281
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
[TBL] [Abstract][Full Text] [Related]
27. Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas.
Bosic M; Kirchner M; Brasanac D; Leichsenring J; Lier A; Volckmar AL; Oliveira C; Buchhalter I; Stögbauer F; Zivkovic-Perisic S; Goeppert B; Schirmacher P; Penzel R; Endris V; Stenzinger A
Pathology; 2018 Apr; 50(3):327-332. PubMed ID: 29269125
[TBL] [Abstract][Full Text] [Related]
28. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Chen L; Yang L; Yao L; Kuang XY; Zuo WJ; Li S; Qiao F; Liu YR; Cao ZG; Zhou SL; Zhou XY; Yang WT; Shi JX; Huang W; Hu X; Shao ZM
Nat Commun; 2018 Apr; 9(1):1357. PubMed ID: 29636477
[TBL] [Abstract][Full Text] [Related]
29. PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.
Zhou J; Imani S; Shasaltaneh MD; Liu S; Lu T; Fu J
Mol Biol Rep; 2022 Mar; 49(3):1799-1816. PubMed ID: 34816327
[TBL] [Abstract][Full Text] [Related]
30. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
[TBL] [Abstract][Full Text] [Related]
31. Juvenile papillomatosis of the breast (Swiss cheese disease) has frequent associations with PIK3CA and/or AKT1 mutations.
Guillet C; Rechsteiner M; Bellini E; Choschzick M; Moskovszky L; Dedes K; Papassotiropoulos B; Varga Z
Hum Pathol; 2020 Apr; 98():64-73. PubMed ID: 32088208
[TBL] [Abstract][Full Text] [Related]
32. Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
Jouali F; Marchoudi N; Talbi S; Bilal B; El Khasmi M; Rhaissi H; Fekkak J
BMC Cancer; 2018 Sep; 18(1):900. PubMed ID: 30227836
[TBL] [Abstract][Full Text] [Related]
33. Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.
Zheng S; He S; Liang Y; Tan Y; Liu Q; Liu T; Lu X
Mol Biomed; 2024 Apr; 5(1):13. PubMed ID: 38616230
[TBL] [Abstract][Full Text] [Related]
34. AKT1 and PIK3CA activating mutations in Moroccan bladder cancer patients´ biopsies and matched urine.
El Ahanidi H; El Azzouzi M; Arrouchi H; Alaoui CH; Tetou M; Bensaid M; Oukabli M; Ameur A; Al Bouzidi A; El Mzibri M; Attaleb M
Pan Afr Med J; 2022; 41():59. PubMed ID: 35317488
[TBL] [Abstract][Full Text] [Related]
35. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
[TBL] [Abstract][Full Text] [Related]
36. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
Ismail SI; Mahmoud IS; Msallam MM; Sughayer MA
Leuk Res; 2010 Jun; 34(6):824-6. PubMed ID: 20022634
[TBL] [Abstract][Full Text] [Related]
37. Syringocystadenoma Papilliferum of the Anogenital Area and Buttocks: A Report of 16 Cases, Including Human Papillomavirus Analysis and HRAS and BRAF V600 Mutation Studies.
Konstantinova AM; Kyrpychova L; Nemcova J; Sedivcova M; Bisceglia M; Kutzner H; Zamecnik M; Sehnalkova E; Pavlovsky M; Zateckova K; Shvernik S; Spurkova Z; Michal M; Kerl K; Kazakov DV
Am J Dermatopathol; 2019 Apr; 41(4):281-285. PubMed ID: 30398985
[TBL] [Abstract][Full Text] [Related]
38. Ectopic hidradenoma papilliferum of eyelid: A rare entity with diagnostic challenge.
Shukla P; Malaviya AK
Indian J Pathol Microbiol; 2018; 61(2):287-289. PubMed ID: 29676381
[TBL] [Abstract][Full Text] [Related]
39. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
[TBL] [Abstract][Full Text] [Related]
40. Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands.
Konstantinova AM; Shelekhova KV; Imyanitov EN; Iyevleva A; Kacerovska D; Michal M; Kazakov DV
Am J Dermatopathol; 2017 May; 39(5):358-362. PubMed ID: 28291131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
